Fulcrum Says FDA Lifts Clinical Hold On FTX-6058 For Sickle Cell Disease; Stock Climbs In Premarket

Fulcrum Therapeutics, Inc. (FULC) announced Tuesday that the U.S. Food and Drug Administration has lifted the clinical hold on the Investigational New Drug or IND application for FTX-6058 for the potential treatment of sickle-cell disease or SCD.

from RTT - Before the Bell https://ift.tt/7stYI8K
via IFTTT